Pulmonary embolism future or investigational therapies: Difference between revisions
Rim Halaby (talk | contribs) No edit summary |
Rim Halaby (talk | contribs) |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
There are several ongoing studies on future therapies for the treatment and prevention of [[venous thromboembolism]] (VTE). The APEX study is a multicenter, randomized, active-controlled efficacy and safety study comparing extended duration [[betrixaban]] with standard of care [[enoxaparin]] for the prevention of [[VTE]] in acute medically ill patients. MARINER is a randomized, double-blind, placebo-controlled, event-driven, multicenter study in patients who are hospitalized for a specific acute medical illness and have other risk factors for [[VTE]] that aims to evaluate [[rivaroxaban]] in the prevention of symptomatic [[VTE]] events and VTE-related deaths for a period of 45 days post-hospital discharge. | There are several ongoing studies on future therapies for the treatment and prevention of [[venous thromboembolism]] (VTE). The APEX study is a multicenter, randomized, active-controlled efficacy and safety study comparing extended duration [[betrixaban]] with standard of care [[enoxaparin]] for the prevention of [[VTE]] in acute medically ill patients.[http://clinicaltrials.gov/ct2/show/study/NCT01583218?term=APEX+and+betrixaban&rank=1] MARINER is a randomized, double-blind, placebo-controlled, event-driven, multicenter study in patients who are hospitalized for a specific acute medical illness and have other risk factors for [[VTE]] that aims to evaluate [[rivaroxaban]] in the prevention of symptomatic [[VTE]] events and VTE-related deaths for a period of 45 days post-hospital discharge.[http://clinicaltrials.gov/ct2/show/study/NCT02111564?term=MARINER&rank=1] | ||
==References== | ==References== | ||
Revision as of 20:55, 11 July 2014
|
Pulmonary Embolism Microchapters |
|
Diagnosis |
|---|
|
Pulmonary Embolism Assessment of Probability of Subsequent VTE and Risk Scores |
|
Treatment |
|
Follow-Up |
|
Special Scenario |
|
Trials |
|
Case Studies |
|
Pulmonary embolism future or investigational therapies On the Web |
|
FDA on Pulmonary embolism future or investigational therapies |
|
CDC on Pulmonary embolism future or investigational therapies |
|
Pulmonary embolism future or investigational therapies in the news |
|
Blogs on Pulmonary embolism future or investigational therapies |
|
Directions to Hospitals Treating Pulmonary embolism future or investigational therapies |
|
Risk calculators and risk factors for Pulmonary embolism future or investigational therapies |
Editor(s)-In-Chief: The APEX Trial Investigators, C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]
Overview
There are several ongoing studies on future therapies for the treatment and prevention of venous thromboembolism (VTE). The APEX study is a multicenter, randomized, active-controlled efficacy and safety study comparing extended duration betrixaban with standard of care enoxaparin for the prevention of VTE in acute medically ill patients.[3] MARINER is a randomized, double-blind, placebo-controlled, event-driven, multicenter study in patients who are hospitalized for a specific acute medical illness and have other risk factors for VTE that aims to evaluate rivaroxaban in the prevention of symptomatic VTE events and VTE-related deaths for a period of 45 days post-hospital discharge.[4]